Changing Landscape of DLBCL Treatment: ADCs, Bispecific Antibodies, CAR T Therapies, and Combinations – Live

Description

Program Description

---

Take Me to the Event Registration

To better define classification, molecular characterization, genetic subtypes, risk stratification, and managing diffuse large B cell lymphoma (DLBCL) with antigen-drug conjugates (ADCs), bispecific antibodies (BsAbs), chimeric antigen receptor T-cell (CAR T), an oral selective inhibitor of exportin 1 (XPO1) therapies, and best practices for managing AEs. This activity will focus on the following:

DLBCL – Classification, molecular characterization, genetic subtypes of DLBCL.

• Cell of origin (COO) – Gene expression profiling (GEP) of regular and DLBCL cells
• Molecular Features – The C-MYC is a proto-oncogene located in chromosome 8q24
• Genetic Subtypes – Categories include the MCD, BN2, N1, and EZB subtypes.

Risk stratification – PET/CT imaging and circulating tumor DNA in prognosticating patients with DLBCL.

Upfront Therapy – Chemo-chemoimmunotherapy with R-CHOP +/− radiation for limited-stage disease

Relapsed/refractory (R/R) DLBCL – Novel therapies such as ADCs, CAR T, BsAbs, and XPO1

• Antigen-Drug Conjugates (ADCs)
  • Brentuximab vedotin in combination with lenalidomide, and rituximab
  • Polatuzumab vedotin in addition to rituximab-bendamustine (BR) or BR alone
  • Loncastuximab tesirine as a single agent
  • Tafasitamab in combination with lenalidomide, bendamustine and R-CHOP
• Bispecific Antibodies (BsAbs)
  • Mosunetuzumab, Glofitamab, Epcoritamab, and Odronextamab
• Protein kinase C-beta inhibitor
  • Enzastaurin
• CAR T-Cell Therapies
  • Axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel)
• Oral selective inhibitor of exportin 1 (XPO1) – Selinexor

Adverse events management – Identification of AEs associated with novel therapies and best practices for managing AEs

• Cytokine Release Syndrome (CRS)
  • CRS – Cardiovascular complications
  • Surveillance for Cardiovascular Toxicity
  • CRS management
• • Tocilizumab
  • Corticosteroids
  • Supportive Care
• Movement and neurocognitive treatment-emergent adverse events (MNTs)
  • Preventive strategies
  • Monitoring strategies
  • Management strategies

Agenda

---

Discuss the classification, molecular characterization, genetic subtypes, risk stratification, and upfront therapy of DLBCL
Ken Young, MD, PhD

Discuss novel therapies such as ADCs, CAR Ts, BsAbs, XPO1, combinations for R/R DLBCL, and strategies to monitor adverse effects
Christopher Flowers, MD, MS, FASCO

Intended Audience

---

This activity is designed to meet the educational needs of medical oncologists, pathologists, physician assistants, nurse practitioners, nurses, and other healthcare professionals who treat patients with DLBCL.

Commercial Supporter

---

Supported by an educational grant from Pfizer